Re: Cant believe I just missed a buy at 4.50 by 5 cents grrr
Some other interesting notes.
-- Follow on from year end conf call, but they mentioned looking for a FDA approval for 853, soraya at the end of 2021 (suggesting a 3-4 month approval timeline from fda) if the data is inline with what was seen before. Again I have to imagine that comes from the FDA themselves.
This was probally mentioned before but 1H data 2020 for BPDCN, 632 to facility the conversation with the FDA for a pivotal trial for 632, possible with breakthrough designation. Conversation 2H 2020. The start of that pivotal trial is the gateway where Jazz has to opt in or potentially lose out on 632.